Helicobacter Pylori Infection Market Size (7MM) was ~USD 2,672.5 million in 2022 and is projected to grow by 2034, estimates DelveInsight

(Albany, USA) DelveInsight's report, "Helicobacter Pylori Infections Market Insights, Epidemiology, and Market Forecast - 2034," delivers an in-depth analysis of the H. pylori infection market across the United States, EU5, and Japan. The study includes historical and forecasted epidemiology, current and emerging treatment patterns, market size projections from 2020-2034, and detailed drug-level market share assessments. Additionally, the report evaluates treatment pathways, major market drivers, limitations, and areas of unmet clinical need to identify growth opportunities and future market potential.

Request for a Free Sample Report @ Helicobacter Pylori Infections Market Forecast- https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some facts of the Helicobacter Pylori Infections Market Report
• In the 7MM, the total diagnosed prevalence of helicobacter pylori infection were estimated to be approximately 321,217,226 in 2022, of which the US accounted for around 37%, while EU4 and the UK accounted for nearly 43%, and Japan accounted for approximately 20% of the total diagnosed prevalent cases.
• Among the 7MM, the US accounted for nearly 118,650,370 total diagnosed prevalent cases of helicobacter pylori infection, in 2022. These cases are expected to increase during the study period due to an increase in disease awareness and diagnosis.
• As per DelveInsight analysis, EU4 and the UK accounted for around 138,397,508 diagnosed prevalent cases of helicobacter pylori infection in 2022. These cases are expected to change during the study period (2020-2034).
• Among the EU4 and the UK, France accounted for the highest diagnosed prevalent cases of helicobacter pylori infection, representing nearly 23% of the cases, followed by Germany and Italy, while the UK had the least cases in 2022.
• According to estimates based on DelveInsight's epidemiology model, helicobacter pylori infection exhibits a higher male preponderance than females in the US. Of the total diagnosed prevalent cases in the US, nearly 52% were males and 48% were females, in 2022.
• DelveInsight forecasts steady growth in the Helicobacter pylori (H. pylori) infections market, with the market expected to expand at a healthy CAGR through 2034.
• Across the 7MM, the H. pylori infections market was valued at roughly USD 2,672.5 million in 2022 and is anticipated to rise consistently over the 2023-2034 forecast period.
• The leading H. pylori infections Companies such as Servatus Biopharmaceuticals, Cinclus Pharma Holding AB, Crestone, EpiVax, Iguana Biotechnology, ImevaX GmbH, ImmunoBiology, Luoxin Pharmaceuticals, Nexbiome Therapeutics, Recce Pharmaceuticals, RedHill Biopharma Ltd, SCG Cell Therapy Pte Ltd, Shanghai High-Tech Bioengineering Co. Ltd, Takeda Pharmaceutical, TenNor Therapeutics, Trio Medicines, Xiamen Encheng Pharmaceutical Co. Ltd, among others.
• Promising Helicobacter pylori infection Therapies such as Rifasutenizole (TNP-2198), SVT1C4610, Vonoprazan, SQ109, Tegoprazan, IMX-101, CRS3123, and others.

Helicobacter Pylori Infections Overview
Helicobacter pylori (H. pylori) infection is a common bacterial condition caused by Helicobacter pylori, typically acquired during childhood and persisting if untreated. The bacterium colonizes the stomach lining, leading to chronic gastritis, peptic ulcers, and increasing the risk of gastric cancer. Transmission occurs mainly through contaminated food, water, or person-to-person contact. Many individuals remain asymptomatic, while others experience abdominal pain, nausea, bloating, or indigestion. Diagnosis is made through stool antigen tests, urea breath tests, blood antibody tests, or endoscopic biopsy. Standard treatment involves combination antibiotic therapy with acid-suppressing agents to eradicate the bacteria and prevent complications.

Do you know what will be the Helicobacter Pylori Infections market share in 7MM by 2034 @ Helicobacter Pylori Infections Market Outlook- https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Helicobacter Pylori Infections Market Outlook
In 2022, the Helicobacter pylori (H. pylori) infection market across the 7MM was valued at approximately USD 2,672.5 million, with steady growth expected through 2034. The United States dominated the market at USD 1,064.8 million, supported by rising awareness and the introduction of newer treatment options. The combined EU4 and UK market reached USD 1,028.3 million, representing around 38% of the total 7MM market. Within Europe, France generated the highest revenue (USD 237.3 million), closely followed by Germany (USD 221.2 million), while the UK accounted for the smallest share. Japan contributed USD 579.4 million, placing it second overall, with significant expansion anticipated by 2034. The H. pylori infection market is categorized based on therapy types. Major approved treatments include TALICIA and VOQUEZNA in the U.S., OMECLAMOX-Pak and PYLERA across the U.S. and EU, and Japan-specific regimens such as VONOSAP, VONOPION, TAKECAB, RABECURE, and RABEFINE. Additionally, several pipeline candidates - most notably rifasutenizole (TNP-2198) are currently being investigated.

Helicobacter Pylori Infections Epidemiology
• Total Helicobacter Pylori Infection Diagnosed Prevalent Cases
• Helicobacter Pylori Infection Gender-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases

Interested to know how the emerging diagnostic approaches will be contributing in increased Helicobacter Pylori Infections diagnosed prevalence pool? Download report @ Helicobacter Pylori Infections Patient Pool Forecast- https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Helicobacter Pylori Infections Drugs Uptake
Rifasutenizole (TNP-2198): TenNor Therapeutics
Rifasutenizole (TNP-2198) is a novel multitarget drug conjugate exhibiting a synergistic mechanism of action, providing potent bactericidal activity against drug-resistant H. pylori strains while maintaining a very low spontaneous resistance rate. Its therapeutic potential extends to infections including H. pylori, bacterial vaginosis, and Clostridioides difficile.

TNP-2198 has received support from China's National Major New Drug Innovation grant and holds IND approval and QIDP designation from the U.S. FDA for H. pylori treatment. The program has completed five clinical trials in China and is currently in a multi-center, randomized, double-blind, bismuth-containing quadruple therapy-controlled Phase III study, designed to evaluate a safe, efficient, and simplified eradication regimen compatible with urea breath test (UBT) monitoring. This strategy may enable large-scale H. pylori screening and eradication to reduce gastric cancer incidence in high-risk populations. Additionally, TNP-2198 is under investigation in Phase II trials for bacterial vaginosis and C. difficile infection.

Helicobacter Pylori Infections Competitive Landscape
• TALICIA (RHB-105): RedHill Biopharma
• VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK: Phathom Pharmaceuticals
• TAKECAB (vonoprazan): Takeda Pharmaceutical/Otsuka Pharmaceutical
• PYLERA: Juvisé Pharmaceuticals/AbbVie
• Rifasutenizole (TNP-2198): TenNor Therapeutics
• BGA-1901: Nexbiome therapeutics
• Linaprazan glurate: Cinclus Pharma
• Esomeprazole: Elpen Pharmaceutical
• TNP-2198: TenNor Therapeutics
• Vonoprazan: Phathom Pharmaceuticals
• Tegoprazan: HK inno.N Corporation
• Levofloxacin: Deva Holding A.S.
• Lansoprazole (Lanton): Meridian Bioscience, Inc.
• Vonoprazan: Takeda
• RHB-105: RedHill Biopharma
• rabeprazole sodium: Janssen Cilag Pharmaceutica
• TAK-438: Takeda
• Ilaprazole + Amoxicillin: Il-Yang Pharm
• Omeprazole, amoxicillin, clarithromycin: Forest Laboratories


Download report to know which TOP 3 therapies will be capturing the largest Helicobacter Pylori Infections market share by 2034? Click here @ Helicobacter Pylori Infections Drugs and Therapies- https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Helicobacter Pylori Infections Therapeutics Assessment
Major key companies are working proactively in the Helicobacter Pylori Infections Therapeutics market to develop novel therapies which will drive the Helicobacter Pylori Infections treatment markets in the upcoming years are RedHill Biopharma Ltd, Takeda Pharmaceutical, Recce Pharmaceuticals, TenNor Therapeutics, Nexbiome Therapeutics, ImevaX GmbH, Iguana Biotechnology, SCG Cell Therapy Pte Ltd, Xiamen Encheng Pharmaceutical Co. Ltd., Crestone, Trio Medicines, Luoxin Pharmaceuticals, Shanghai High-Tech Bioengineering Co. Ltd., ImmunoBiology, Cinclus Pharma Holding AB, Servatus Biopharmaceuticals, EpiVax, and several other emerging players.

Do you know how Rifasutenizole (TNP-2198) and SVT1C4610 market launch will be impacting the Helicobacter Pylori Infections market CAGR? Download sample report @ Helicobacter Pylori Infections Therapeutics Market- https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Helicobacter Pylori Infections Report Key Insights
1. Overview of the Helicobacter pylori infections patient population
2. Evaluation of market size and emerging trends for Helicobacter pylori infections
3. Analysis of major competitive players within the H. pylori treatment landscape
4. Market dynamics, including primary growth drivers and key challenges
5. Potential opportunities within the H. pylori infections market
6. Review of available therapeutic strategies for managing H. pylori infections
7. Assessment of the developmental pipeline for upcoming H. pylori therapies
8. Summary of current treatment guidelines and clinical management practices
9. Examination of how new and emerging therapies will influence the future market

Table of Contents
1. Key Insights
2. Executive Summary
3. Helicobacter Pylori Infections Competitive Intelligence Analysis
4. Helicobacter Pylori Infections Market Overview at a Glance
5. Helicobacter Pylori Infections Disease Background and Overview
6. Helicobacter Pylori Infections Patient Journey
7. Helicobacter Pylori Infections Epidemiology and Patient Population
8. Helicobacter Pylori Infections Treatment Algorithm, Current Treatment, and Medical Practices
9. Helicobacter Pylori Infections Unmet Needs
10. Key Endpoints of Helicobacter Pylori Infections Treatment
11. Helicobacter Pylori Infections Marketed Products
12. Helicobacter Pylori Infections Emerging Therapies
13. Helicobacter Pylori Infections Seven Major Market Analysis
14. Attribute Analysis
15. Helicobacter Pylori Infections Market Outlook (7 major markets)
16. Helicobacter Pylori Infections Access and Reimbursement Overview
17. KOL Views on the Helicobacter Pylori Infections Market
18. Helicobacter Pylori Infections Market Drivers
19. Helicobacter Pylori Infections Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.